Eli Lilly (LLY)
1,347.11
-4.01 (-0.30%)
NYSE · Last Trade: Nov 21st, 2:47 AM EST
Detailed Quote
| Previous Close | 1,351.12 |
|---|---|
| Open | 1,362.38 |
| Bid | 1,345.50 |
| Ask | 1,348.50 |
| Day's Range | 1,341.76 - 1,372.05 |
| 52 Week Range | 850.51 - 1,475.25 |
| Volume | 3,546,876 |
| Market Cap | 1.29T |
| PE Ratio (TTM) | 43.72 |
| EPS (TTM) | 30.8 |
| Dividend & Yield | 6.920 (0.51%) |
| 1 Month Average Volume | 3,049,759 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
Eli Lilly's revenue is climbing at a pace AbbVie can't match, yet AbbVie trades at a noticeably lower earnings multiple.
Via The Motley Fool · November 20, 2026
The dividend is hefty -- and it's been growing briskly, too.
Via The Motley Fool · November 20, 2026
Compound earnings can do a lot of heavy lifting.
Via The Motley Fool · November 19, 2026
Eli Lilly (NYSE:LLY): Strong Growth Paired With a High-Quality Technical Setupchartmill.com
Via Chartmill · November 18, 2026
Anthropic just pulled off the biggest IPO ever. Whether it’s worth $2 trillion is another question.
Via The Motley Fool · November 19, 2026
GLP-1 Treatments, Anticancer Research, and Emerging Therapeutic Technologies Are Driving the Next Chapter of Pharmaceutical Innovation
By FN Media · Via GlobeNewswire · November 19, 2026
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:LLY),(NYSE:HIMS),(TSXV:PAIN),(CSE:VLAB) EQNX::TICKER_END
Via FinancialNewsMedia · November 19, 2026
Both teams see promise in the business, but Team Rule Breakers wants to see a few more quarters of results, while Team Hidden Gems is open to buying.
Via The Motley Fool · November 18, 2026
Investors can build life-changing wealth in the stock market with a combination of patience and consistency.
Via The Motley Fool · November 18, 2026
Even a small share of the massive market for weight loss drugs could lead to a significant increase in this company's share price.
Via The Motley Fool · November 18, 2026
Lilly's revenue growth is turbocharged by its weight-loss pipeline, while Novo's global footprint and far lower valuation raise a tougher question about risk versus reward.
Via The Motley Fool · November 17, 2026
Eloralintide-Peptide.com Breaks Down Lilly's ObesityWeek 2026 EloraTZP Data and the First Participant-Reported Findings on Eloralintide. New analysis separates what changed at ObesityWeek from what did not: responder rates and exit-interview data are new, the headline weight-loss figures are not.
Via Press Release Distribution Service · November 17, 2026
Eli Lilly’s pipeline is an embarrassment of riches.
Via The Motley Fool · November 16, 2026
Concentrated pharma exposure delivered 31% returns over one year, while active healthcare management achieved 18%.
Via The Motley Fool · November 15, 2026
Hint: It’s not a bad investment idea.
Via The Motley Fool · November 15, 2026
One fund owns the big drugmakers that pay dividends. The other owns the broader biotech field, where stocks swing more. Here is which fits long-term investors.
Via The Motley Fool · November 15, 2026
Lower acquisition costs and flat overhead could let LifeMD keep more of each subscriber's revenue as patient volume grows.
Via The Motley Fool · November 14, 2026
Firefly's $1.4 billion backlog and Redwire's 45.8% revenue growth point to very different bets, and the valuation gap may be the deciding factor.
Via The Motley Fool · November 14, 2026
Even a small share of the weight loss drug market could lead to a substantial increase in the company's share price.
Via The Motley Fool · November 13, 2026
LifeMD (NASDAQ:LFMD) lowered its full-year revenue and adjusted EBITDA outlook after third-quarter sales fell short of its forecast, as the virtual healthcare company cut marketing spending and took longer than expected to launch branded GLP-1 fulfillment arrangements.
Revenue for the quarter ended
Via MarketBeat · November 12, 2026
The world's largest healthcare company is making shrewd investments in its future.
Via The Motley Fool · November 12, 2026
Lilly's experimental GLP-1 is effective in treating osteoarthritic knee pain.
Via The Motley Fool · November 12, 2026
Hims & Hers stock sank after a Q3 earnings and revenue miss, lower EBITDA guidance, subscriber declines, and an expanding FTC lawsuit over privacy and billing practices.
Via MarketBeat · November 12, 2026
Novo Nordisk lived up to expectations for its Wegovy pill in the third quarter, but it still has more work ahead.
Via The Motley Fool · November 11, 2026
These drugmakers offer very different risk-reward profiles.
Via The Motley Fool · November 11, 2026
